Tigecycline: A glycylcycline antimicrobial agent

Clinical Therapeutics

Volumn 28, Issue 8, 2006, Pages 1079-1106

  Doan, Thien Ly ^a   Fung, Horatio B ^b   Mehta, Dhara ^b   Riska, Paul F ^b  

^a LONG ISLAND JEWISH MEDICAL CENTER   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

complicated intra abdominal infection; complicated skin and skin structure infection; glycylcycline; tigecycline

Indexed keywords

AMIKACIN; AMPICILLIN; ANTIBIOTIC AGENT; AZTREONAM; BETA LACTAM ANTIBIOTIC; CARBAPENEM DERIVATIVE; CEFTAZIDIME; CEPHALOSPORIN DERIVATIVE; CILASTATIN PLUS IMIPENEM; CIPROFLOXACIN; CLAVULANIC ACID; ERTAPENEM; ERYTHROMYCIN; EXTENDED SPECTRUM BETA LACTAMASE; GLYCYLCYCLINE DERIVATIVE; LEVOFLOXACIN; LINEZOLID; MEROPENEM; MINOCYCLINE; OXACILLIN; OXYTETRACYCLINE; PENICILLIN DERIVATIVE; PIPERACILLIN PLUS TAZOBACTAM; SULTAMICILLIN; TAZOBACTAM; TETRACYCLINE DERIVATIVE; TIGECYCLINE; TIMENTIN; UNINDEXED DRUG; VANCOMYCIN;

ABDOMINAL INFECTION; ABDOMINAL PAIN; ABSCESS; AGE; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANAEROBIC BACTERIUM; ANEMIA; ANOREXIA; ANTIBIOTIC RESISTANCE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASTHENIA; BACTERIAL INFECTION; BACTEROIDES; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CLOSTRIDIUM DIFFICILE; CONSTIPATION; COUGHING; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DOSE CALCULATION; DRUG ACTIVITY; DRUG APPROVAL; DRUG EFFICACY; DRUG ELIMINATION; DRUG FORMULARY; DRUG HALF LIFE; DRUG INDICATION; DRUG INFORMATION; DRUG MANUFACTURE; DRUG PROTEIN BINDING; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; DUODENUM PERFORATION; DUODENUM ULCER; DYSPEPSIA; DYSPNEA; ENTEROBACTERIACEAE; FEVER; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL DISEASE; GASTROINTESTINAL SYMPTOM; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HEADACHE; HEALING; HUMAN; HYPERTENSION; HYPOKALEMIA; HYPOPHOSPHATEMIA; HYPOPROTEINEMIA; HYPOTENSION; IN VITRO STUDY; IN VIVO STUDY; INFECTION; INFECTION COMPLICATION; INJECTION SITE REACTION; INSOMNIA; KIDNEY FUNCTION; LIVER DISEASE; LIVER DYSFUNCTION; LYMPHOCYTOPENIA; MAINTENANCE DRUG DOSE; MEDLINE; METABOLIC DISORDER; MULTIDRUG RESISTANCE; NAUSEA; NEUROLOGIC DISEASE; NONHUMAN; NUTRITIONAL DISORDER; OXACILLIN RESISTANT STAPHYLOCOCCUS AUREUS; PAIN; PARTIAL THROMBOPLASTIN TIME; PERIPHERAL EDEMA; PHLEBITIS; PROTEIN SYNTHESIS; PRURITUS; RASH; RESPIRATORY TRACT DISEASE; SEX; SIDE EFFECT; SKIN APPENDAGE DISEASE; SKIN DISEASE; SKIN INFECTION; STAPHYLOCOCCUS AUREUS; SWEAT GLAND DISEASE; SWEATING; THROMBOCYTOPENIA; THROMBOCYTOSIS; ULCER PERFORATION; UNITED STATES; VANCOMYCIN RESISTANT ENTEROCOCCUS; VOMITING;

ANIMALS; ANTI-BACTERIAL AGENTS; CLINICAL TRIALS; CLINICAL TRIALS AS TOPIC; DRUG INTERACTIONS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ECONOMICS, PHARMACEUTICAL; HUMANS; MICROBIAL SENSITIVITY TESTS; MINOCYCLINE; SKIN DISEASES, BACTERIAL; SOFT TISSUE INFECTIONS;

EID: 33748583751     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2006.08.011     Document Type: Article

References (103)

1. Diekema D.J., BootsMiller B.J., Vaughn T.E., et al. Antimicrobial resistance trends and outbreak frequency in United States hospitals. Clin Infect Dis 38 (2004) 78-85
2. Hiramatsu K., Hanaki H., Ino T., et al. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J Antimicrob Chemother 40 (1997) 135-136
3. Centers for Disease Control and Prevention (CDC). Staphylococcus aureus resistant to vancomycin-United States, 2002. MMWR Morb Mortal Wkly Rep 51 (2002) 565-567
4. [published correction appears in MMWR Morb Mortal Wkly Rep. 2002;51:931]. Miller D., Urdaneta V., and Weltman A. Public health dispatch: Vancomycin-resistant Staphylococcus aureus-Pennsylvania, 2002. Case report. MMWR Morb Mortal Wkly Rep 51 (2002) 902
5. Weber J.T. Community-associated methicillin-resistant Staphylococcus aureus. Clin Infect Dis Suppl 4 (2005) S269-S272
6. Bratu S., Mooty M., Nichani S., et al. Emergence of KPC-possessing Klebsiella pneumoniae in Brooklyn, New York: Epidemiology and recommendations for detection. Antimicrob Agents Chemother 49 (2005) 3018-3020
7. Nordmann P., and Poirel L. Emerging carbapenemases in gram-negative aerobes. Clin Microbiol Infect 8 (2002) 321-331
8. Lolans L., Queenan A.M., Bush K., et al. First nosocomial outbreak of Pseudomonas aeruginosa producing an integronborne metallo-beta-lactamase (VIM-2) in the United States. Antimicrob Agents Chemother 49 (2005) 3538-3540
9. Walsh T.R. The emergence and implications of metallo-betalactamases in gram-negative bacteria. Clin Microbiol Infect 11 Suppl 6 (2005) 2-9
10. Available at. Infectious Diseases Society of America. Bad Bugs, No Drugs: As Antibiotic Discovery Stagnates... A Public Health Crisis Brews. Accessed February 10 (2006). http://www.idsociety.org/pa/IDSA/Paper4finalweb.pdf
11. Scheinfeld N. Tigecycline: A review of a new glycylcycline antibiotic. J Dermatolog Treat 16 (2005) 207-212
12. Tygacil [package insert]. Philadelphia, Pa: Wyeth Pharmaceuticals; 2005.
13. Pankey G.A. Tigecycline. J Antimicrob Chemother. 56 (2005) 470-480
14. Garrison M.W., Neumiller J.J., and Setter S.M. Tigecycline: An investigational glycylcycline antimicrobial with activityagainst resistant gram-positive organisms. Clin Ther 27 (2005) 12-22
15. Zhanel G.G., Homenuik K., Nichol K., et al. The glycylcyclines: A comparative review with the tetracyclines. Drugs 64 (2004) 63-88
16. Rubinstein E., and Vaughan D. Tigecycline: A novel glycylcyline. Drugs 65 (2005) 1317-1336
17. Chopra I. New developments in tetracycline antibiotics: Glycylcyclines and tetracycline efflux pump inhibitors. Drug Resist Updat 5 (2002) 119-125
18. Chopra I. Glycylcyclines: Third-generation tetracycline antibiotics. Curr Opin Pharmacol 1 (2001) 464-469
19. Bergeron J., Ammirati M., Danley D., et al. Glycylcyclines bind to the high-affinity tetracycline ribosomal binding site and evade Tet(M)- and Tet(O)-medicated ribosomal protection. Antimicrob Agents Chemother 40 (1996) 2226-2228
20. Fritsche T.R., Kirby J.T., and Jones R.N. In vitro activity of tigecycline (GAR-936) tested against 11,859 recent clinical isolates associated with community-acquired respiratory tract and gram-positive cutaneous infections. Diagn Microbiol Infect Dis 49 (2004) 201-209
21. Hoban D.J., Bouchillon S.K., Johnson B.M., et al., Tigecycline Evaluation and Surveillance Trial (TEST Program) Group. In vitro activity of tigecycline against 6792 gram-negative and gram-positive clinical isolates from the global Tigecycline Evaluation and Surveillance Trial (TEST program, 2004). Diagn Microbiol Infect Dis 52 (2005) 215-227
22. Sader H.S., Jones R.N., Dowzicky M.J., and Fritsche T.R. Antimicrobial activity oftigecycline tested against nosocomial bacterial pathogens from patients hospitalized in the intensive care unit. Diagn Microbiol Infect Dis 52 (2005) 203-208
23. Sader H.S., Jones R.N., Stilwell M.G., et al. Tigecycline activity tested against 26,474 bloodstream infection isolates: A collection from 6 continents. Diagn Microbiol Infect Dis 52 (2005) 181-186
24. Fritsche T.R., Sader H.S., Stilwell M.G., et al. Potency and spectrum of tigecycline tested against an international collection of bacterial pathogens associated with skin and soft tissue infections (2000-2004). Diagn Microbiol Infect Dis 52 (2005) 195-201
25. Fritsche T.R., Sader H.S., Stilwell M.G., et al. Antimicrobial activity of tigecycline tested against organisms causing community-acquired respiratory tract infection and noso comial pneumonia. Diagn Microbiol Infect Dis 52 (2005) 187-193
26. Gales A.C., and Jones R.N. Antimicrobial activity and spectrum of the new glycylcycline, GAR-936 tested against 1203 recent clinical bacterial isolates. Diagn Microbiol Infect Dis 36 (2000) 19-36
27. Fritsche T.R., Strabala P.A., Sader H.S., et al. Activity of tigecycline tested against a global collection of Enterobacteriaceae, including tetracycline-resistant isolates. Diagn Microbiol Infect Dis 52 (2005) 209-213
28. Jacobus N.V., McDermott L.A., Ruthazer R., and Snydman D.R. In vitro activities of tigecycline against the Bacteroides fragilis group. Antimicrob Agents Chemother 48 (2004) 1034-1036
29. Goldstein E.J., Citron D.M., Merriam C.V., et al. Comparative in vitro activities of GAR-936 against aerobic and anaerobic animal and human bite wound pathogens. Antimicrob Agents Chemother 44 (2000) 2747-2751
30. Bradford P.A., Weaver-Sands D.T., and Petersen P.J. In vitro activity of tigecycline against isolates from pa tients enrolled in phase 3 clinical trials of treatment for complicated skin and skin-structure infections and complicated intra-abdominal infections. Clin Infect Dis 41 Suppl 5 (2005) S315-S332
31. Abstract E-329. Bouchillon S., Stevens T., Johnson J., et al. Methicillin-resistant Staphylococcus aureus (1030) collected from a recent global population: Tigecycline in vitro evaluation. Abstracts of the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy [on CD-ROM] (2005), American Society for Microbiology, Washington, DC
32. Abstract E-330. Johnson B., Bouchillon S., Stevens T., et al. Vancomycin-resistant enterococci (VRE): A global problem: Evaluation of tigecycline against recent isolates from multi-centers globally. Abstracts of the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy [on CD-ROM] (2005), American Society for Microbiology, Washington, DC
33. Fritsche T.R., and Jones R.N. Antimicrobial activity of tigecycline (GAR936) tested against 3498 recent iso lates of Staphylococcus aureus recovered from nosocomial and community-acquired infections. Int J Antimicrob Agents 24 (2004) 567-571
34. LaPlante K.L., and Rybak M.J. Clinical glycopeptide-intermediate staphylococci tested against arbekacin, daptomycin, and tigecycline. Diagn Microbiol Infect Dis 50 (2004) 125-130
35. Tenover F.C., Weigel L.M., Appelbaum P.C., et al. Vancomycin-resistant Staphylococcus aureus isolate from a patient in Pennsylvania. Antimicrob Agents Chemother 48 (2004) 275-280
36. Bozdogan B., Esel D., Whitener C., et al. Antibacterial susceptibility of a vancomycin-resistant Staphylococcus aureus strain isolated at the Hershey Medical Center. J Antimicrob Chemother 52 (2003) 864-868
37. Abstract E-332. Johnson B., Bouchillon S., Stevens T., et al. Determining tigecycline's in vitro activity against multi-drug re sistant Enterobacteriaceae from the TEST program-global data. Abstracts of the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy [on CD-ROM] (2005), American Society for Microbiology, Washington, DC
38. Abstract E-2058. Fritsche T.R., Strabala P., Sader H.S., and Jones R.N. Activity of tigecycline tested against tetracycline-resistant Enterobacteriaceae. Abstracts of the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy [on CD-ROM] (2004), American Society for Microbiology, Washington, DC
39. Abstract E-2064. Betriu C., Gomez M., Rodriguez I., et al. In vitro activity of tigecycline and comparative antimicrobial agents against ampicillin-resistant Haemophilus influenzae isolates. Abstracts of the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy [on CD-ROM] (2004), American Society for Microbiology, Washington, DC
40. Deshpande L.M., Gales A.C., and Jones R.N. GAR-936 (9-t-butylglycylamidominocycline) susceptibility test development for streptococci, Haemophilus influenzae and Neisseria gonorrhoeae: Preliminary guidelines and interpretive criteria. Int J Antimicrob Agents 18 (2001) 29-35
41. Document M27-S2. Clinical and Laboratory Standards Institute. Quality Control Minimal Inhibitory Concentration (MIC) Limits for Broth Microdilution and MIC Interpretive Breakpoints: Informational Supplement-Second Edition (2006), CLSI, Wayne, Pa
42. Bradford P.A., Petersen P.J., Young M., et al. Tigecycline MIC testing by broth dilution requires use of fresh medium or addition of the biocatalytic oxygen-reducing reagent oxyrase to standardize the test method. Antimicrob Agents Chemother 49 (2005) 3903-3909
43. Hope R., Warner M., Mushtaq S., et al. Effect of medium type, age and aeration on the MICs of tigecycline and classical tetracyclines. J Antimicrob Chemother 56 (2005) 1042-1046
44. Kenny G.E., and Cartwright F.D. Susceptibility of Mycoplasma hominis, M. pneumoniae and Ureaplasma urealyticum to GAR-936, dalfopristin, dirithromycin, evernimicin, gatifloxacin, linezolid, moxifloxacin, quinupristin-dalfopristin, and telithromycin compared to their susceptibilities to reference macrolides, tetracyclines, and quinolones. Antimicrob Agents Chemother 45 (2001) 2604-2608
45. Roblin P.M., and Hammerschlag M.R. In vitro activity of GAR-936 against Chlamydia pneumoniae and Chlamydia trachomatis. Int J Antimicrob Agents 16 (2000) 61-63
46. Wallace Jr. R.J., Brown-Elliott B.A., Crist C.J., et al. Comparison of the in vitro activity of the glycylcycline tige cycline (formerly GAR-936) with those of tetracycline, minocycline, and doxycycline against isolates of nontuberculous mycobacteria. Antimicrob Agents Chemother 46 (2002) 3164-3167
47. Muralidharan G., Micalizzi M., Speth J., et al. Pharmacokinetics of tigecycline after single and multiple doses in healthy subjects. Antimicrob Agents Chemother 49 (2005) 220-229
48. Postier R.G., Green S.L., Klein S.R., et al., Tigecycline 200 Study Group. Results of a multicenter, randomized, open-label efficacy and safety study of two doses of tigecycline for complicated skin and skin-structure infections in hospitalized patients. Clin Ther 26 (2004) 704-714
49. Abstract A-10. van Wart S., Cirincione B., Hirankarn S., et al. Population pharmacokinetics of tigecycline in phase 1 subjects. Abstracts of the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy [on CD-ROM] (2004), American Society for Microbiology, Washington, DC
50. Sun H.K., Ong C.T., Umer A., et al. Pharmacokinetic profile of tigecycline in serum and skin blister fluid of healthy subjects after multiple intravenous administrations. Antimicrob Agents Chemother 49 (2005) 1629-1632
51. Conte Jr. J.E., Golden J.A., Kelly M.G., and Zurlinden E. Steady-state serum and intrapulmonary pharmacokinetics and pharmacodynamics of tigecycline. Int J Antimicrob Agents 25 (2005) 523-529
52. Abstract A-18. Rodvold K.A., Gotfried M.H., Cwik M., et al. Tigecycline (TGC) concentrations (Cp) in lung tissue, cere brospinal fluid (CSF), and bile of human subjects. Abstracts of the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy [on CD-ROM] (2005), American Society for Microbiology, Washington, DC
53. Abstract W5301. Available at. Hoffman M., DeMaio W., Jordan R., et al. Metabolic disposition of [14C]tigecycline in human volun teers following intravenous infusion. Accessed February 10, 2006. AAPS J 6 Suppl 1 (2004). http://www.aapspharmaceutica.com/search/abstract_view.asp?id=495&ct=04Ab stracts.
54. Muralidharan G., Fruncillo R.J., Micalizzi M., et al. Effects of age and sex on single-dose pharmacokinetics of tigecycline in healthy subjects. Antimicrob Agents Chemother 49 (2005) 1656-1659
55. Abstract A-22. Troy S.M., Muralidharan G., Micalizzi M., et al. The effects of renal disease on the pharmacokinetics of tigecy cline (GAR-936). Abstracts of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy [on CD-ROM] (2003), American Society for Microbiology, Chicago, III
56. Abstract A-22. Garrison M.W., and Neumiller J.J. Comparative pharmacodynamic activity of tigecycline (GAR-936) against quinolone resistant S. pneumoniae, methicillin-resistant S. aureus and vancomycin-resistant enterococci. Abstracts of the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy [on CD-ROM] (2005), American Society for Microbiology, Washington, DC
57. Hoellman D.B., Pankuch G.A., Jacobs M.R., and Appelbaum P.C. Antipneumococcal activities of GAR-936 (a new glycylcycline) compared to those of nine other agents against penicillin-susceptible and -resistant pneumococci. Antimicrob Agents Chemother 44 (2000) 1085-1088
58. Abstract A-1821. Reese A.M., and Burgess D.S. In vitro pharmacodynamics and post-antibiotic effects (PAE) of tigecycline against gram-negative bacteria. Abstracts of the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy [on CD-ROM] (2005), American Society for Microbiology, Washington, DC
59. Projan S.J. Preclinical pharmacology of GAR-936, a novel glycylcycline antibacterial agent. Pharmacotherapy 20 (2000) 2195-2235
60. Lefort A., Lafaurie M., Massias L., et al. Activity and diffusion of tigecycline (GAR-936) in experimental enterococcal endocarditis. Antimicrob Agents Chemother 47 (2003) 216-222
61. van Ogtrop M.L., Andes D., Stamstad T.J., et al. In vivo pharmacodynamic activities of two glycylcyclines (GAR-936 and WAY 152,288) against various gram-positive and gram-negative bacteria. Antimicrob Agents Chemother 44 (2000) 943-949
62. Mercier R.C., Kennedy C., and Meadows C. Antimicrobial activity of tigecycline (GAR-936) against Enterococccus faecium and Staphylococcus aureus used alone and in combination. Pharmacotherapy 22 (2002) 1517-1523
63. Patel R., Rouse M.S., Piper K.E., and Steckelberg J.M. In vitro activity of GAR-936 against vancomycin-resistant entero cocci, methicillin-resistant Staphylococcus aureus and penicillin-resistant Streptococcus pneumoniae. Diagn Microbiol Infect Dis 38 (2000) 177-179
64. Petersen P.J., Labthavikul P., Jones C.H., and Bradford P.A. In vitro antibacterial activities of tigecycline in com bination with other antimicrobial agents determined by chequerboard and time-kill kinetic analysis. J Antimicrob Chemother. 57 (2006) 573-576
65. Meagher A.K., Ambrose P.G., Grasela T.H., and Ellis-Grosse E.J. Pharmacokinetic/pharmacodynamic profile for tigecycline-a new glycylcycline antimicrobial agent. Diagn Microbiol Infect Dis. 52 (2005) 165-171
66. Meagher A.K., Ambrose P.G., Grasela T.H., and Ellis-Grosse E.J. The pharmacokinetic and pharmacodynamic pro file of tigecycline. Clin Infect Dis 41 Suppl 5 (2005) 5333-5340
67. Abstract A-1155. Passarell J.A., Liolios K., Meagher A.K., et al. Exposure-response analysis of the efficacy of tigecycline in patients with complicated intra-abdominal infections. Abstracts of the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy [on CD-ROM] (2005), American Society for Microbiology, Washington, DC
68. Fluit A.C., Florijn A., Verhoef J., and Milatovic D. Presence of tetracycline resistance determinants and suscep tibility to tigecycline and minocycline. Antimicrob Agents Chemother 49 (2005) 1636-1638
69. Abstract C2-295. Jones C.H., Tuckman M., Howe A.Y., et al. Occurrence of methicillin and tetracycline resistance genes among Staphylococcus aureus isolates from tigecycline phase 3 clinical trials for complicated skin and skin structure infections using diagnostic PCR analysis. Abstracts of the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy [on CD-ROM] (2005), American Society for Microbiology, Washington, DC
70. Tuckman M., Petersen P.J., and Projan S.J. Mutations in the interdomain loop region of the tetA(A) tetracycline re sistance gene increase efflux of minocycline and glycylcyclines. Microb Drug Resist 6 (2000) 277-282
71. McAleese F., Petersen P., Ruzin A., et al. A novel MATE family efflux pump contributes to the reduced suscepti bility of laboratory-derived Staphylococcus aureus mutants to tigecycline. Antimicrob Agents Chemother 49 (2005) 1865-1871
72. Dean C.R., Visalli M.A., Projan S.J., et al. Efflux-mediated resistance to tigecycline (GAR-936) in Pseudomonas aeruginosa PAO1. Antimicrob Agents Chemother 47 (2003) 972-978
73. Visalli M.A., Murphy E., Projan S.J., and Bradford P.A. AcrAB multidrug efflux pump is associated with reduced levels of susceptibility to tigecycline (GAR-936) in Proteus mirabilis. Antimicrob Agents Chemother 47 (2003) 665-669
74. Ruzin A., Keeney D., and Bradford P.A. AcrAB efflux pump plays a role in decreased susceptibility to tigecycline in Morganella morganii. Antimicrob Agents Chemother 49 (2005) 791-793
75. Ruzin A., Visalli M.A., Keeney D., and Bradford P.A. Influence of transcriptional activator RamA on expression of multidrug efflux pump AcrAB and tigecycline susceptibility in Klebsiella pneumoniae. Antimicrob Agents Chemother 49 (2005) 1017-1022
76. Abstract C1-1198. Ruzin A., Keeney D., Visalli M.A., and Bradford P.A. AcrAB efflux-mediated decreased susceptibility to tigecycline in Enterobacter species. Abstracts of the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy [on CD-ROM] (2004), American Society for Microbiology, Washington, DC
77. Abstract Cl-1419. Keeney D., Ruzin A., McAleese M., and Bradford P.A. E coli clinical isolates with decreased tigecycline suscepti bility exhibit altered expression of MarA, AcrAB and other genes. Abstracts of the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy [on CD-ROM] (2005), American Society for Microbiology, Washington, DC
78. Murphy T.M., Deitz J.M., Petersen P.J., et al. Therapeutic efficacy of GAR936, a novel glycylcycline, in a rat model of experimental endocarditis. Antimicrob Agents Chemother 44 (2000) 3022-3027
79. Yin L.Y., Lazzarini L., Li F., et al. Comparative evaluation of tigecycline and vancomycin, with and without rifampicin, in the treatment of methicillin-resistant Staphylococcus aureus experimental osteomyelitis in a rabbit model. J Antimicrob Chemother 55 (2005) 995-1002
80. Edelstein P.H., Weiss W.J., and Edelstein M.A. Activities of tigecycline (GAR-936) against Legionella pneumophila in vitro and in guinea pigs with L. pneumophila pneumonia. Antimicrob Agents Chemother. 47 (2003) 533-540
81. Nannini E.C., Pai S.R., Singh K.V., and Murray B.E. Activity of tigecycline (GAR-936), a novel glycylcycline, against Enterococci in the mouse peritonitis model. Antimicrob Agents Chemother 47 (2003) 529-532
82. Petersen P.J., Jacobus N.V., Weiss W.J., et al. In vitro and in vivo antibacterial activities of a novel glycylcycline, the 9-t-butylglycylamido derivative of minocycline (GAR-936). Antimicrob Agents Chemother 43 (1999) 738-744
83. Sacchidanand S., Penn R.L., Embil J.M., et al. Efficacy and safety of tigecy cline monotherapy compared with vancomycin plus aztreonam in patients with complicated skin and skin structure infections: Results from a phase 3, randomized, double-blind trial. Int J Infect Dis 9 (2005) 251-261
84. Breedt J., Teras J., Gardovskis J., and Tigecycline 305 cSSSI Study Group. Safety and efficacy of tigecycline in treatment of skin and skin structure infections: Results of a double-blind phase 3 comparison study with vancomycin-aztreonam. Antimicrob Agents Chemother 49 (2005) 4658-4666
85. Oliva M.E., Rekha A., Yellin A., et al., 301 Study Group. A multicenter trial of the efficacy and safety of ti gecycline versus imipenem/cilastatin in patients with complicated intraabdominal infections. BMC Infect Dis 5 (2005) 88
86. Abstract L-992C. Dartois N., Gioud-Paquet M., Ellis-Grosse E.J., Loh E., and Tigecycline 306 Study Group. Tigecycline vs imipenem/cilastatin for treatment of complicated intra-abdominal in fections. Abstracts of the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy [on CD-ROM] (2004), American Society for Microbiology, Washington, DC
87. Available at: http://www.clinicaltrials.gov/ct/search?term=tigecycline &submit=search Accessed February 10, 2006.
88. Ellis-Grosse E.J., Babinchak T., Dartois N., et al., Tigecycline 300 cSSSI Study Group and the Tigecycline 305 cSSSI Study Group. The efficacy and safety of tigecycline in the treat ment of skin and skin-structure in fections: Results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam. Clin Infect Dis 41 Suppl 5 (2005) 5341-5353
89. Vancocin hydrochloride (2003), Baxter Health care Corporation, Deerfield, III
90. BabinchakT Ellis-Grosse E., Dartois N., et al., Tigecycline 301 Study Group and the Tigecycline 306 Study Group. The efficacy and safety of tigecycline for the treat ment ofcomplicated intra-abdominal infections: Analysis of pooled clinical trial data. Clin Infect Dis 41 Suppl 5 (2005) 5354-5367
91. Abstract A-1403. Sesoko S., Umemura K., and Nakashima M. Pharmacokinetics, safety and tolerability of tigecycline (GAR-936) in healthy Japanese males. Abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy [on CD-ROM] (2002), American Society for Microbiology, San Diego, Calif
92. Copenhagen, Denmark. Abstract 894. Passarell J.A., Meagher A., Liolios K.A., et al. Pharmacokinetic/pharmaco dynamic model of the tolerability of tigecycline in healthy volunteers. Program and abstracts of the 15th European Congress of Clinical Microbiology and Infectious Diseases. April 2-5 (2005)
93. Nathwani D. Tigecycline: Clinical evidence and formulary positioning. Int J Antimicrob Agents 25 (2005) 185-192
94. Abstract A-460. Zimmerman J.J., Harper D., Matschke K., et al. Pharmacokinetics and pharmacodynamics of tigecycline and digoxin coadministered to healthy men. Abstracts of the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy [on CD-ROM] (2004), American Society for Microbiology, Washington, DC
95. Abstract A-21. Raible D.G., Zimmerman J.J., Harper D.M., and Speth J.L. Pharmacokinetics and pharmacodynamics of tigecy cline and warfarin coadministered to healthy subjects. Abstracts of the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy [on CD-ROM] (2005), American Society for Microbiology, Washington, DC
96. 2006 Drug Topics Red Book (2006), Thompson Medical Economics, Montvale, NJ
97. Ramirez J., and Ahkee S. Switching to oral antibiotics: A cost-savings strategy in the hospitalized patient. Drug Benefit Trends 8 (1996) 20-22
98. Ramirez J., and Ahkee S. Switching to oral antibiotics: A cost-savings strategy in the hospitalized patient. Drug Benefit Trends 8 (1996) 28
99. Ramirez J., and Ahkee S. Switching to oral antibiotics: A cost-savings strategy in the hospitalized patient. Drug Benefit Trends 8 (1996) 34
100. Livermore D.M. Tigecycline: What is it, and where should it be used?. J Antimicrob Chemother 56 (2005) 611-614
101. Evans M.E., Feola D.J., and Rapp R.P. Polymyxin B sulfate and colistin: Old antibiotics for emerging multiresistant gram-negative bacteria. Ann Pharmacother 33 (1999) 960-967
102. Ong C.T., Babalola C.P., Nightingale C.H., and Nicolau D.P. Penetration, efflux, and intracellular activity of tigecy cline in human polymorphonuclear neutrophils (PMNs). J Antimicrob Chemother. 56 (2005) 498-501
103. Abstract 413. Tombs N.L. Tissue distribution of GAR-936, a broad-spectrum antibiotic, in male rats. Abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy [on CD-ROM] (1999), Calif American Society for Microbiology, San Francisco